Is Prostate Cancer Surgery Really Beneficial to Men With Early Stage Cancer of the Prostate?
Surgical Procedures can help in treating early stage prostate cancer in men. However, it seems that this treatment options does not augur well for men.The lives of men who undergo this surgical procedure as a treatment may not be saved after all.
A new study has identified that compared with watchful waiting, surgery for prostate cancer may not be a good for men who are seeking for relieve from cancer of the prostate. This new study was published in The New England Journal of Medicine, and it is sure provides lots of interesting details.
Below is an online extract that may want to have you question the benefits of prostate cancer surgery:
A new study shows that prostate cancer surgery, which often leaves men impotent or incontinent, does not appear to save the lives of men with early-stage disease, who account for most cases, and many of these men would do just as well to choose no treatment at all.
The findings were based on the largest-ever clinical trial comparing surgical removal of the prostate with a strategy known as “watchful waiting.” They add to growing concerns that prostate cancer detection and treatment efforts over the past 25 years, particularly in the United States, have been woefully misguided, rendering millions of men impotent, incontinent and saddled with fear about a disease that was unlikely ever to kill them in the first place. About 100,000 to 120,000 radical prostatectomy surgeries are performed in the United States each year.
“I think this is game-changing,” said Dr. Leonard Marks, a professor of urology at the University of California, Los Angeles, who was not involved in the study. “What this study does is call attention to the fact that there are a lot of prostate cancers that are diagnosed today that are not dangerous.”
Even so, the research, published Wednesday in The New England Journal of Medicine and paid for by the Department of Veterans Affairs, the National Cancer Institute and the Agency for Healthcare Research and Quality, is unlikely to settle the debate about the best course of care for men with prostate cancer.
An editorial accompanying the report argued that the study of 731 men, while important, is still too small to draw definitive conclusions about the relative benefits of radical prostatectomy. In addition, slightly more men who did not undergo surgery developed bone metastases over the course of the 15-year study. There was no statistical difference in risk of death from prostate cancer or any cause among men who were randomly assigned to surgery or to an observation group. There was also a suggestion that men with very high scores on a prostate cancer screening test were more likely to benefit from surgery.
The study included only men with early-stage disease, about half of whom learned of their cancer as a result of the prostate specific antigen, or P.S.A., screening blood test. About 81 percent of men with prostate cancer have early-stage or localized cancer, which means it has not spread beyond the prostate. But the findings are not relevant to men with more advanced disease, who may benefit from aggressive treatment, said Dr. Ian Thompson, director of the cancer therapy and research center at the University of Texas Health Science Center in San Antonio.
“The real point is that we shouldn’t focus on finding every prostate cancer because, as this study and all the screening studies show, the majority that you find don’t need to be found,’’ said Dr. Thompson, an author of the editorial. “What we should focus our screening on and our testing on are patients who are likely to have more aggressive tumors in which treatment seems to make a difference.”
This year, about 242,000 men will receive a diagnosis of prostate cancer, largely because of screening for high levels of P.S.A. in the blood. About 28,000 men die of prostate cancer each year, making it the second-biggest cancer killer of men, second only to lung cancer. Even so, large studies now show that early detection by P.S.A. screening makes little, if any, difference in whether a man dies from prostate cancer.
In May, the United States Preventive Services Task Force issued a controversial recommendation against regular P.S.A. screening. The task force concluded that the test offers little, if any benefit, yet subjects men to anxiety and painful biopsies and often puts them on the course of invasive and risky treatment. But several medical groups have criticized the finding, and P.S.A. testing remains an entrenched part of men’s health care at middle age.
The latest research, called the Prostate Cancer Intervention Versus Observation Trial, or Pivot, focuses on what happens after a man receives a diagnosis of early-stage cancer, often as a result of a P.S.A. test. The men in the study were randomly assigned either to surgical removal of the prostate or to an observation group, where a man’s cancer was monitored but not treated unless it showed signs of progressing. Although the study originally set out to recruit 2,000 men, the researchers could not reach that goal and revised the research plan to include 731 men.
By the end of the 15-year study, 354 men had died, but most of them had died of from a cause other than prostate cancer. There was no statistical difference in overall mortality rates in the surgical group, which had 171 deaths, compared with the observation group, which had 183 deaths.
During the study, only 52 men, or about 7 percent of the study subjects, died of prostate cancer, but again there was no statistical difference in the prostate cancer mortality rate between the groups. Click here to read the full extract.
The above extract reveals the implications of going for surgery. It brings to mind once again the ongoing debate generated by the recommendations of the United States Preventive Services Task Force (USPSTF) that stops the screening of men with prostate cancer.
Compared to the benefits of surgery, the above extract is rooting for watchful waiting or active surveillance for prostate cancer. Watchful waiting will pose fewer risks than surgery.
This is an interesting study you should really consider or think about. You can still choose not to treat your early stage prostate cancer!
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:
(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)
- Early Stage Prostrate Cancer Treatment
- Treating Early Stage Prostate Cancer
- Early Prostate Cancer Treatments Relieve Men with Lower Urinary Tract Symptoms (LUTS)
- Prostate Surgery and Safety in Older Men
- Men Who Embrace Multidisciplinary Treatment Team Opt More For Active Surveillance Than Surgery Or Radiation
- Early Hormone Therapy Radiation for Men with Prostate Cancer
- Casodex and Prostate Cancer – Lupron and Casodex as Early Stage Fighters
- Bladder Surgery May Be Needed As a Follow Up To Prostate Cancer Surgery
- Robotic Prostate Cancer Surgery Too Costly than Open Surgery – Offers No Extraordinary Benefits
- Follow – Up Bladder Surgery Not Likely with Robotic Prostate Cancer Surgery – Dr. David Samadi
- Localized Prostate Cancer Treatment – Robot Assisted Surgery Better Than Open Surgery
- Diagnosis And Treatment Health Prostate Cancer – Early Screening
- 4th Stage Prostate Cancer – Information about This Deadly Stage of the Disease